Eli Lilly/$LLY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$828B
45.22
$20.44
0.46
$5.80
0.65%
Price and volume
Market cap
$828B
Beta
0.46
52-week high
$955.46
52-week low
$623.78
Average daily volume
3.9M
Dividend rate
$5.80
Financial strength
Current ratio
1.546
Quick ratio
0.724
Long term debt to equity
171.664
Total debt to equity
178.516
Dividend payout ratio (TTM)
28.28%
Interest coverage (TTM)
26.44%
Profitability
EBITDA (TTM)
28,728.6
Gross margin (TTM)
83.03%
Net profit margin (TTM)
30.99%
Operating margin (TTM)
45.16%
Effective tax rate (TTM)
18.18%
Revenue per employee (TTM)
$1,260,000
Management effectiveness
Return on assets (TTM)
17.60%
Return on equity (TTM)
96.47%
Valuation
Price to earnings (TTM)
45.219
Price to revenue (TTM)
13.974
Price to book
34.8
Price to tangible book (TTM)
72.33
Price to free cash flow (TTM)
117.644
Free cash flow yield (TTM)
0.85%
Free cash flow per share (TTM)
7.857
Dividend yield (TTM)
0.63%
Forward dividend yield
0.65%
Growth
Revenue change (TTM)
45.41%
Earnings per share change (TTM)
121.02%
3-year revenue growth (CAGR)
26.66%
10-year revenue growth (CAGR)
11.67%
3-year earnings per share growth (CAGR)
45.39%
10-year earnings per share growth (CAGR)
24.87%
3-year dividend per share growth (CAGR)
15.24%
10-year dividend per share growth (CAGR)
11.29%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Bulls say / Bears say
In Q3 2025, Eli Lilly’s revenue jumped 54% year-over-year to $17.6 billion driven by blockbuster sales of Mounjaro and Zepbound, and the company raised its full-year guidance on stronger-than-expected demand (FT)
The U.S. FDA approved Inluriyo for adult patients with advanced breast cancer after a late-stage trial showed a 38% reduction in progression or death risk, enhancing Eli Lilly’s oncology portfolio (Reuters)
Eli Lilly committed $6.5 billion to build a Houston plant dedicated to producing orforglipron, positioning it to scale next-generation obesity treatments in a market projected to generate up to $25 billion at peak (Reuters)
Eli Lilly halted a mid-stage trial of bimagrumab for muscle preservation in combination with tirzepatide after a strategic review, marking a significant setback for its obesity pipeline diversification (Reuters)
A federal appeals court upheld a $183.7 million Medicaid fraud judgment against Eli Lilly for underreporting price increases between 2005 and 2017, exposing the company to material financial and reputational risks (Reuters)
Eli Lilly executives reported ongoing talks with the Trump administration on drug pricing reform lack clarity on implementation, creating uncertainty around future pricing and reimbursement strategies (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
CNBC19 hours ago
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Benzinga22 hours ago
Lilly's obesity drug Mounjaro becomes India's top-selling drug by value in October
Reuters1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $828B as of November 08, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 45.22 as of November 08, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of November 08, 2025, the dividend rate is $5.8 and the yield is 0.65%. Eli Lilly has a payout ratio of 28.28% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for December 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.